LIFECORE BIOMEDICAL, INC. current report, Q1 FY2017

SEC Filing Summary: Landec Corporation (Form 8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Landec Corporation on March 17, 2017, reporting events that occurred on March 14, 2017. The filing addresses corporate governance changes regarding the Board of Directors. Note: The request metadata referenced "LIFECORE BIOMEDICAL, INC.", but the source text explicitly identifies the registrant as Landec Corporation.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.

Material Changes

  • Board Expansion: The authorized number of directors was increased from eight (8) to nine (9).
  • New Director Election: Debbie Carosella was elected as a Class 2 Director and appointed to the Food Innovation Committee.
  • Conflict of Interest Disclosure: Ms. Carosella has no material interest in any transaction exceeding $120,000 involving the Company since the beginning of the last fiscal year.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.

Investor Verification Checklist

  • Verify the background and qualifications of the newly elected director, Debbie Carosella.
  • Confirm the composition of the Food Innovation Committee following the appointment.
  • Review the Company's proxy statement or subsequent filings for details on the rationale behind increasing the Board size.